Q-omics provides the consensus-scored CTSLP8 profile across patient tissues and cancer cell-line models. CTSLP8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CTSLP8 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, CTSLP8 RNA expression shows 8,541 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, and THYM as cancer lineages where CTSLP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTSLP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTSLP8 survival associations across molecular data types. CTSLP8 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTSLP8 RNA expression–survival associations across cancer types. High CTSLP8 expression shows unfavorable associations in COAD, LUSC, LIHC, DLBC, KICH and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CTSLP8 RNA expression.
This table summarizes CTSLP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CTSLP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTSLP8 shows lower tumor expression in COAD, LUSC, LUAD, KICH, KIRP and KIRC. The COAD box plot shows higher CTSLP8 RNA expression in normal versus tumor tissue (log2 FC = −0.192, t-test p < 0.001).
This table shows molecular features associated with CTSLP8 in patient tissues and cancer cell lines. In patient samples, CTSLP8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
